Australia's Dimerix soars on commercialisation deal with Everest Medicines
16/06/2026 03:36
BUZZ-Australia's Dimerix soars on commercialisation deal with Everest Medicines ** Shares of Australia's Dimerix DXB.AX rise as much as 51.5% to A$0.250, their highest since April 30
** Clinical stage biopharmaceutical firm says it entered into an exclusive agreement with Everest Medicines 1952.HK
** Agreement to commercialise DMX-200 for the treatment of Focal
Segmental Glomerulosclerosis, a rare kidney disease, in Greater China, South Korea and Southeast Asia** Around 13.1 mln shares change hands, nearly 6.3x 30-day average
** DXB down 64.1% YTD
(Reporting by Keshav Singh Chundawat in Bengaluru)
Recent news on Everest Medicines
See all newsBrief: Everest Medicines Says NMPA Approves Cardamyst (Etripamil) NDA For PSVT In Adults In China
Brief: Everest Medicines Enters Commercialization Collaboration With Hainan Herui Pharmaceutical
Brief: Everest Medicines Says CBC Group Purchases 712,000 Everest Medicines Shares For Hk$19.2 Million From 16 To 17 June
Australia's Dimerix soars on commercialisation deal with Everest Medicines
Brief: Dimerix Ltd Licenses Dmx200 To Everest For China And Asia Region